Infectious Disease
RSSArticles
-
Infectious Disease Updates
ID: An Arbiter of Death? Preventing Recurrent UTI with Probiotics
-
Diagnostic Uncertainty in Community-Acquired Pneumonia
A national retrospective cohort study from the Veterans Administration found a high rate of diagnostic discordance for patients admitted and discharged for community-acquired pneumonia (CAP). Improvement in the diagnosis of CAP is needed.
-
Mucormycosis Remains Highly Lethal
Mucormycosis continues to be associated with a high mortality rate. Polymerase chain reaction may speed diagnosis and allow earlier initiation of therapy. There appears to be no evidence supporting the use of combination as opposed to single agent (liposomal amphotericin B) therapy.
-
Outbreak of Marburg Virus Disease in Rwanda
A rising number of cases of Marburg virus disease, which is caused by one of the most virulent human pathogens, have been reported in Rwanda. Marburg virus infections in humans are rare but can present with a rapidly progressive febrile illness that can lead to multi-organ failure and shock with case-fatality rates of up to 80% to 90%.
-
Eat Your Fruits and Veggies to Decrease HPV Infection
Data from a large-scale national health and nutrition survey from 2003-2016 were used to examine the risk of genital human papillomavirus infection in 10,543 women ages 18-59 years.
-
COVID-19 Vaccine mRNA Suspension for Injection (Comirnaty, Spikevax)
The Food and Drug Administration has approved and granted emergency use authorization for updated messenger ribonucleic acid (mRNA) COVID-19 vaccines.
-
Out of Africa Again? A New Version of Mpox
A novel mpox clade has emerged in Africa and has the potential for a global epidemic.
-
Infectious Disease Updates
Managing Neurosyphilis; Combatting the Resurgence of Syphilis
-
Does Semaglutide Protect Against Adverse Effects from COVID-19?
Semaglutide recipients who developed COVID-19 had significant protection against the occurrence of adverse outcomes, including death.
-
Twice-Yearly Subcutaneous Lenacapavir Injection Prevents HIV Infection
Subcutaneous injection of lenacapavir every 26 weeks had 100% efficacy in preventing human immunodeficiency virus (HIV) infection in a high-risk population.